Ricerca traslazionaleTranslational Res    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Home_enTranslational Res
Translational Research

 

The IGM belongs to the research Institutions validated for Innovation and Technologic Transfer by the QuESTIO network from Regione Lombardia, thus being a possible partner of SMEs.

 

The IGM is actually involved in project “Meta-Distretti of Excellence” entitled “Innovative processes for the biosynthetic production of antracyclines” supported by the Regione Lombardia for 3 years (2007-2009). This project is based on the cooperation between the IGM and several SMEs, namely Biofin Laboratories SRL (project leader), NaxosPharma SRL, HS Digital SRL, e Solaris Biotechnology SRL. These partners have signed a Temporary Association of SMEs protocol.

 

 

The IGM has been recently granted by the Regione Lombardia for the project “Plant Cell” for 3 years (2010-2012). This project is based on the cooperation between the IGM and several SMEs, namely Biofin Laboratories SRL (project leader), NaxosPharma SRL, Solaris Biotechnology SRL, BiCT, and INDENA. The grant of 200,000 € to IGM covers the research of Drs. Scovassi and Maga, which is focused on the effects of plant extracts on cell proliferation/death of cancer cells, and on viral replication.

 

The R&D division of Areta International and the IGM – CNR has established a collaboration for the development of monoclonal antibodies specific for human DNA ligase I. DNA ligase I is an essential enzyme involved in DNA replication and is required for cell proliferation.
The first results of the collaboration was the generation of 5H5 Mab that is a promising tool for labelling proliferating celles as it can be conveniently used in immunocytochemistry and immunohistochemistry on either frozen or paraffin embedded specimens.
Part of this work, including the performance of this antibody on lynph nodes from patients with non Hodgkin’s lynphoma was published in 2005 on European Journal of Histochemistry (Violo B, Lidonnici MR, Montecucco C, Montecucco A,  2005, Eur J Histochem. 49:349-354).
The 5H5 is in the monoclonal portfolio of Areta and is commercialized.
 

The Research and Development division of the company Diatheva  Ltd. Fano and IGM - CNR, Unit of Bologna have established a collaboration for the development of polyclonal antibodies specific for the human prelamin A. The prelamin A is the precursor of lamin A and is accumulated in serious hereditary and acquired disorders by creating cellular toxicity and causing lipodystrophy and premature aging. 

 

The IGM-CNR has launched the activities of the Italian Network Laminopathies which meets regularly at the Institute of Bologna. The Network aims to bring together and coordinate all the Italian centers involved in clinical practice and research in the field of diseases caused by mutations in the lamin A/C and other proteins of the nuclear envelope. The Italian Laminopathies Network has a website that provides current information on diseases, the centers involved and scientific research progress.


Copyright © 2014 Home_en